The roles of complement 1q (C1q) and Apolipoprotein E (ApoE) in driving Alzheimer's disease (AD) progression might be explained by their associations with neuroinflammation and AD pathology which were previously reported.
Objective
We examined the associations of cerebrospinal fluid (CSF) C1q and ApoE with CSF neuroinflammatory biomarkers and AD core biomarkers, as well as explored whether C1q mediated the associations of CSF ApoE with these biomarkers.
Methods
Here, we analyzed CSF proteomics data from Alzheimer's Disease Neuroimaging Initiative (ADNI) using two different ADNI proteomics datasets—SomaScan (n = 579)and multiple reaction monitoring (MRM[n = 207]). Linear regression analyses were conducted to explore the association of CSF ApoE and C1q. The mediation model and structural equation model (SEM) were conducted to explore the associations of ApoE and C1q with AD biomarkers.
Results
Multiple linear regression showed that CSF ApoE was positively associated with CSF C1q in total participants and Alzheimer's continuum participants. Mediation analyses indicated that C1q mediated the associations of CSF ApoE with CSF T-tau, P-tau, sTREM2 and GFAP (mediation proportions range from 15.06 to 44.64%; all the p values < 0.05) but not with CSF amyloid-β and progranulin (PGRN). The SEM yielded similar results.
Conclusions
Our findings suggest that C1q is linked to ApoE, and it mediates the associations of ApoE with T-tau, P-tau, sTREM2, GFAP, indicating C1q association with ApoE might be involved in AD progression.
2023 Alzheimer's disease facts and figures. Alzheimers Dement2023; 19: 1598–1695.
2.
FinderVH. Alzheimer's disease: a general introduction and pathomechanism. J Alzheimers Dis2010; 22: 5–19.
3.
HenekaMTCarsonMJEl KhouryJ, et al.Neuroinflammation in Alzheimer's disease. Lancet Neurol2015; 14: 388–405.
4.
GuanPPGeTQWangP. As a potential therapeutic target, C1q induces synapse loss via inflammasome-activating apoptotic and mitochondria impairment mechanisms in Alzheimer's disease. J Neuroimmune Pharmacol2023; 18: 267–284.
5.
YamazakiYZhaoNCaulfieldTR, et al.Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol2019; 15: 501–518.
6.
ChenYStricklandMRSorannoA, et al.Apolipoprotein E: structural insights and links to Alzheimer disease pathogenesis. Neuron2021; 109: 205–221.
7.
HuangYMahleyRW. Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases. Neurobiol Dis2014; 72: 3–12.
8.
YinCAckermannSMaZ, et al.Apoe attenuates unresolvable inflammation by complex formation with activated C1q. Nat Med2019; 25: 496–506.
9.
QinQWangMYinY, et al.The specific mechanism of TREM2 regulation of synaptic clearance in Alzheimer's disease. Front Immunol2022; 13: 845897.
10.
GiovannoniFQuintanaFJ. The role of astrocytes in CNS inflammation. Trends Immunol2020; 41: 805–819.
11.
VoetSPrinzMvan LooG. Microglia in central nervous system inflammation and multiple sclerosis pathology. Trends Mol Med2019; 25: 112–123.
12.
CarterSFHerholzKRosa-NetoP, et al.Astrocyte biomarkers in Alzheimer's disease. Trends Mol Med2019; 25: 77–95.
13.
JonssonTStefanssonHSteinbergS, et al.Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med2013; 368: 107–116.
14.
KwonHSKohSH. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener2020; 9: 42.
15.
VeitchDPWeinerMWAisenPS, et al.Using the Alzheimer's disease neuroimaging initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimers Dement2022; 18: 824–857.
16.
VeitchDPWeinerMWAisenPS, et al.Understanding disease progression and improving Alzheimer's disease clinical trials: recent highlights from the Alzheimer's disease neuroimaging initiative. Alzheimers Dement2019; 15: 106–152.
17.
AisenPSPetersenRCDonohueMC, et al.Clinical core of the Alzheimer's disease neuroimaging initiative: progress and plans. Alzheimers Dement2010; 6: 239–246.
18.
SchindlerSEGrayJDGordonBA, et al.Cerebrospinal fluid biomarkers measured by elecsys assays compared to amyloid imaging. Alzheimers Dement2018; 14: 1460–1469.
19.
SpellmanDSWildsmithKRHonigbergLA, et al.Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's disease neuroimaging initiative (ADNI) CSF. Proteomics Clin Appl2015; 9: 715–731.
20.
KleinbergerGYamanishiYSuárez-CalvetM, et al.TREM2 Mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med2014; 6: 243ra286.
21.
HanssonOSeibylJStomrudE, et al.CSF Biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement2018; 14: 1470–1481.
22.
SperlingRAAisenPSBeckettLA, et al.Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 280–292.
23.
AlbertMSDeKoskySTDicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 270–279.
24.
McKhannGMKnopmanDSChertkowH, et al.The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement2011; 7: 263–269.
25.
BaronRMKennyDA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol1986; 51: 1173–1182.
26.
ByeonSLeeW. An introduction to causal mediation analysis with a comparison of 2 R packages. J Prev Med Public Health2023; 56: 303–311.
27.
StreinerDL. Building a better model: an introduction to structural equation modelling. Can J Psychiatry2006; 51: 317–324.
28.
JacksonDLGillaspyJAPurc-StephensonR. Reporting practices in confirmatory factor analysis: an overview and some recommendations. Psychol Methods2009; 14: 6–23.
29.
AssmannSFHosmerDWLemeshowS, et al.Confidence intervals for measures of interaction. Epidemiology1996; 7: 286–290.
30.
KnolMJvan der TweelIGrobbeeDE, et al.Estimating interaction on an additive scale between continuous determinants in a logistic regression model. Int J Epidemiol2007; 36: 1111–1118.
31.
ForteaJPeguerolesJAlcoleaD, et al.APOE4 Homozygozity represents a distinct genetic form of Alzheimer's disease. Nat Med2024; 30: 1284–1291.
32.
SchartzNDTennerAJ. The good, the bad, and the opportunities of the complement system in neurodegenerative disease. J Neuroinflammation2020; 17: 354.
33.
NesargikarPNSpillerBChavezR. The complement system: history, pathways, cascade and inhibitors. Eur J Microbiol Immunol (Bp)2012; 2: 103–111.
34.
HongSBeja-GlasserVFNfonoyimBM, et al.Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science2016; 352: 712–716.
35.
StevensBJohnsonMB. The complement cascade repurposed in the brain. Nat Rev Immunol2021; 21: 624–625.
36.
BenoitMEHernandezMXDinhML, et al.C1q-induced LRP1B and GPR6 proteins expressed early in Alzheimer disease mouse models, are essential for the C1q-mediated protection against amyloid-β neurotoxicity. J Biol Chem2013; 288: 654–665.
37.
PisalyaputKTennerAJ. Complement component C1q inhibits beta-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. J Neurochem2008; 104: 696–707.
38.
LiaoFYoonHKimJ. Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease. Curr Opin Lipidol2017; 28: 60–67.
39.
ToledoJBDaXWeinerMW, et al.CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol2014; 127: 621–632.
40.
BartelsTDe SchepperSHongS. Microglia modulate neurodegeneration in Alzheimer's and Parkinson's diseases. Science2020; 370: 66–69.
41.
ChunchaiTChinchapoTSripetchwandeeJ, et al.Lipopolysaccharide exacerbates depressive-like behaviors in obese rats through complement C1q-mediated synaptic elimination by microglia. Acta Physiol (Oxf)2024; 240: e14130.
42.
SchaferDPLehrmanEKKautzmanAG, et al.Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron2012; 74: 691–705.
43.
HuoAWangJLiQ, et al.Molecular mechanisms underlying microglial sensing and phagocytosis in synaptic pruning. Neural Regen Res2024; 19: 1284–1290.
44.
LeeSDevanneyNAGoldenLR, et al.APOE Modulates microglial immunometabolism in response to age, amyloid pathology, and inflammatory challenge. Cell Rep2023; 42: 112196.
45.
HemonnotALHuaJUlmannL, et al.Microglia in Alzheimer disease: well-known targets and new opportunities. Front Aging Neurosci2019; 11: 233.
46.
Scott-HewittNMahoneyMHuangY, et al.Microglial-derived C1q integrates into neuronal ribonucleoprotein complexes and impacts protein homeostasis in the aging brain. Cell2024; 187: 4193–4212.e4124.
47.
ChenWTLuACraessaertsK, et al.Spatial transcriptomics and in situ sequencing to study Alzheimer's disease. Cell2020; 182: 976–991.e919.
48.
EikelenboomPBateCVan GoolWA, et al.Neuroinflammation in Alzheimer's disease and prion disease. Glia2002; 40: 232–239.
49.
AmelimojaradMAmelimojaradMCuiX. The emerging role of brain neuroinflammatory responses in Alzheimer's disease. Front Aging Neurosci2024; 16: 1391517.
50.
SaleemMHerrmannNSwardfagerW, et al.Inflammatory markers in mild cognitive impairment: a meta-analysis. J Alzheimers Dis2015; 47: 669–679.
51.
JendresenCÅrskogVDawsMR, et al.The Alzheimer's disease risk factors apolipoprotein E and TREM2 are linked in a receptor signaling pathway. J Neuroinflammation2017; 14: 59.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
